Association of C34T AMPD1 gene polymorphism with features of metabolic syndrome in patients with coronary artery disease or heart failure

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 69, Issue 1, 2009, Pages 102-112

  Safranow, Krzysztof ^a   Czyzycka, Edyta ^a   Binczak Kuleta, Agnieszka ^a   Rzeuski, Ryszard ^a   Skowronek, Janusz ^a   Wojtarowicz, Andrzej ^a   Jakubowska, Katarzyna ^a   Olszewska, Maria ^a   Loniewska, Beata ^a   Kaliszczak, Robert ^a   Kornacewicz Jach, Zdzislawa ^a   Ciechanowicz, Andrzej ^a   Chlubek, Dariusz ^a  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

Author keywords

AMP deaminase; Congestive heart failure; Diabetes mellitus; Genotype; Glomerular filtration rate; Hypertension; Ischaemic heart disease; Metabolic syndrome X; Obesity

Indexed keywords

ADENOSINE MONOPHOSPHATE DEAMINASE; ADENOSINE MONOPHOSPHATE DEAMINASE 1; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLUCOSE; UNCLASSIFIED DRUG;

ADULT; ALLELE; CLINICAL FEATURE; COMPARATIVE STUDY; CONFERENCE PAPER; CONTROL GROUP; CONTROLLED STUDY; DIABETES MELLITUS; DIET RESTRICTION; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC REGULATION; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE TOLERANCE TEST; HEART FAILURE; HETEROZYGOTE; HIP; HOMOZYGOTE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NEWBORN; OBESITY; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SYSTOLIC BLOOD PRESSURE; WAIST CIRCUMFERENCE; WAIST HIP RATIO;

AMP DEAMINASE; CASE-CONTROL STUDIES; CORONARY ARTERY DISEASE; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HEART FAILURE; HUMANS; KIDNEY FUNCTION TESTS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MULTIVARIATE ANALYSIS; NATRIURETIC PEPTIDE, BRAIN; POLYMORPHISM, SINGLE NUCLEOTIDE; REGRESSION ANALYSIS; WAIST CIRCUMFERENCE;

EID: 61649085695     PISSN: 00365513     EISSN: 15027686     Source Type: Journal    
DOI: 10.1080/00365510802430964     Document Type: Conference Paper

References (31)

1. Morisaki T, Sabina RL, Holmes EW. Adenylate deaminase. A multigene family in humans and rats. J Biol Chem 1990;265:11482-6.
2. Morisaki T, Gross M, Morisaki H, Pongratz D, Zöllner N, Holmes EW. Molecular basis of AMP deaminase deficiency in skeletal muscle. Proc Natl Acad Sci USA 1992;89:6457-61.
3. Norman B, Mahnke-Zizelman DK, Vallis A, Sabina RL. Genetic and other determinants of AMP deaminase activity in healthy adult skeletal muscle. J Appl Physiol 1998;85:1273-8.
4. Sabina RL, Swain JL, Patten BM, Ashizawa T, O'Brien WE, Holmes EW. Disruption of the purine nucleotide cycle. A potential explanation for muscle dysfunction in myoadenylate deaminase deficiency. J Clin Invest 1980;66:1419-23.
5. Gross M. Clinical heterogeneity and molecular mechanisms in inborn muscle AMP deaminase deficiency. Inherit Metab Dis 1997;20:186-92.
6. Tarnopolsky MA, Parise G, Gibala MJ, Graham TE, Rush JW. Myoadenylate deaminase deficiency does not affect muscle anaplerosis during exhaustive exercise in humans. J Physiol 2001;533:881-9.
7. Kalsi KK, Yuen AH, Rybakowska IM, Johnson PH, Slominska E, Birks EJ, Kaletha K, Yakoub MH, Smolensk RT. Decreased cardiac activity of AMP deaminase in subjects with the AMPD1 mutation - a potential mechanism of protection in heart failure. Cardiovasc Res 2003;59:678-84.
8. Loh E, Rebbeck TR, Mahoney PD, DeNofrio D, Swain JL, Holmes EW. Common variant in AMPD1 gene predicts improved clinical outcome in patients with heart failure. Circulation 1999;99:1422-5.
9. Gastmann A, Sigusch HH, Henke A, Reinhardt D, Surber R, Gastmann O, Figulla HR. Role of adenosine monophosphate deaminase-1 gene polymorphism in patients with congestive heart failure (influence on tumor necrosis factor-alpha level and outcome). Am J Cardiol 2004;93:1260-4.
10. Yazaki Y, Muhlestein JB, Carlquist JF, Bair TL, Horne BD, Renlund DG, Andersson JL. A common variant of the AMPD1 gene predicts improved survival in patients with ischemic left ventricular dysfunction. J Card Fail 2004;10:316-20.
11. Anderson JL, Habashi J, Carlquist JF, Muhlestein JB, Horne BD, Bair TL, Pearson RR, Hart N. A common variant of the AMPD1 gene predicts improved cardiovascular survival in patients with coronary artery disease. J Am Coll Cardiol 2000;36:1248-52.
12. Andreassi MG, Botto N, Laghi-Pasini F, Manfredi S, Ghelarducci B, Farneti A, Solinas M, Biagin A, Picano E. AMPD1 (C34T) polymorphism and clinical outcomes in patients undergoing myocardial revascularization. Int J Cardiol 2005;101:191-5.
13. Kolek MJ, Carlquist JF, Thaneemit-Chen S, Lazzeroni LC, Whiting BM, Horne BD, Muhlestein JB, Lavor P, Andersson JL. The role of a common adenosine monophosphate deaminase (AMPD)-1 polymorphism in outcomes of ischemic and nonischemic heart failure. J Card Fail 2005;11:677-83.
14. de Groote P, Lamblin N, Helbecque N, Mouquet F, Hermant X, Amouyel P, Dallongeville J, Bauters C. The impact of the AMPD1 gene polymorphism on exercise capacity, other prognostic parameters, and survival in patients with stable congestive heart failure: a study in 686 consecutive patients. Am Heart J 2006;152:736-41.
15. Collins RP, Palmer BR, Pilbrow AP, Frampton CM, Troughton RW, Yandle TG, Skelton L, Richards AM, Cameron VA. Evaluation of AMPD1 C34T genotype as a predictor of mortality in heart failure and post-myocardial infarction patients. Am Heart J 2006;152:312-20.
16. Goodarzi MO, Taylor KD, Guo X, Quinones MJ, Cui J, Li X, Hang T, Yang H, Holmes E, Hsueh WA, Olefsky J, Rotter JL. Variation in the gene for muscle-specific AMP deaminase is associated with insulin clearance, a highly heritable trait. Diabetes 2005;54:1222-7.
17. Guo SW, Thompson EA. Performing the exact test of Hardy-Weinberg proportion for multiple alleles. Biometrics 1992;48:361-72.
18. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
19. International Diabetes Federation: The IDF consensus worldwide definition of the metabolic syndrome. 2005. Available at: http://www.idf.org.
20. Agewall S, Norman B. Association between AMPD1 gene polymorphism and coagulation factors in patients with coronary heart disease. Pathophysiol Haemost Thromb 2006;35:440-4.
21. Rico-Sanz J, Rankinen T, Joanisse DR, Leon AS, Skinner JS, Wilmore JH, Rao DC, Bouchard C. HERITAGE Family study. Associations between cardiorespiratory responses to exercise and the C34T AMPD1 gene polymorphism in the HERITAGE Family Study. Physiol Genomics 2003;14:161-6.
22. Fischer H, Esbjörnsson M, Sabina RL, Strömberg A, Peyrard-Janvid M, Norman B. AMP deaminase deficiency is associated with lower sprint cycling performance in healthy subjects. J Appl Physiol 2007;103:315-22.
23. Hand BD, Roth SM, Roltsch MH, Park JJ, Kostek MC, Ferrell RE, Brown MD. AMPD1 gene polymorphism and the vasodilatory response to ischemia. Life Sci 2006;79:1413-18.
24. Winder WW, Hardie DG. AMP-activated protein kinase, a metabolic master switch: possible roles in type 2 diabetes. Am J Physiol 1999;277:E1-10.
25. Steinberg GR, Jorgensen SB. The AMP-activated protein kinase: role in regulation of skeletal muscle metabolism and insulin sensitivity. Mini Rev Med Chem 2007;7:519-26.
26. Towler MC, Hardie DG. AMP-activated protein kinase in metabolic control and insulin signaling. Circ Res 2007;100:328-41.
27. Gerbitz KD, Gempel K, Brdiczka D. Mitochondria and diabetes. Genetic, biochemical, and clinical implications of the cellular energy circuit. Diabetes 1996;45:113-26.
28. Bottini E, Gloria-Bottini F. Adenosine deaminase and body mass index in non-insulin-dependent diabetes mellitus. Metabolism 1999;48:949-51.
29. Gloria-Bottini F, Bottini E, Lucarini N, Palmarino R. Further observations on the relationship between adenosine deaminase and body mass. Metab Clin Exp 1999;48:1336.
30. Thong FS, Graham TE. The putative roles of adenosine in insulin- and exercise-mediated regulation of glucose transport and glycogen metabolism in skeletal muscle. Can J Appl Physiol 2002;27:152-78.
31. Palaniappan L, Carnethon MR, Wang Y, Hanley AJ, Fortmann SP, Haffner SM, Wagenknecht L. Predictors of the incident metabolic syndrome in adults: the Insulin Resistance Atherosclerosis Study. Diabetes Care 2004;27:788-93.